What It Really Takes to Bring Innovation To Canada
When I walked into the Thriving Amid Trade Wars panel at the National Pharmaceutical Congress, I expected an economic briefing with charts and forecasts about tariffs. Instead, I walked out thinking about trust, patients, and how innovation survives inside systems that don’t always reward it.
One line still echoes in my mind:
“Do no more harm to the U.S. market.”
That single phrase revealed how fragile our balance really is. Decisions made far beyond Canada’s borders ripple through our ability to invest, attract research, and launch life-changing therapies.
Canada’s challenge isn’t talent or ideas, it’s alignment. We invest less than half of what the U.S. does into research and innovation in life sciences. We’re strong in clinical trials, yet hesitant in commercialization and our regulatory maze leaves new drugs paused for review while patients wait.
Healthcare as an Investment
What struck me most wasn’t frustration, but possibility.
If we start seeing healthcare not as a cost centre but as an investment, everything changes. Innovation stops being a luxury and becomes a growth engine for jobs, discovery, and better outcomes.
Canada could be a leader in global trials, a testing ground for emerging therapies, a bridge between research and patients, but only if we reward innovation instead of slowing it down.
Lean In to Innovation
Another speaker summarized it perfectly:
“Be agile. Gain advantage. Make tough decisions.”
Innovation isn’t about endless resources; it’s about the courage to focus, to invest where it matters, to test early, and learn fast.
And maybe most importantly, to know your audience.
Because whether you’re designing a policy or launching a therapy, innovation always starts with empathy.
Where We Go from Here
Leaving that room, I felt something between optimism and urgency. Canada’s innovation story isn’t broken; it’s unfinished.
We have the science, the people, and the global respect.
What we need now is conviction; to act like healthcare is worth investing in, and to move fast enough that patients don’t have to wait for progress already proven elsewhere.
Maybe Thriving Amid Trade Wars isn’t really about trade at all.
Maybe it’s about the courage to keep innovating when the world gets noisy, to see healthcare as a partnership between science, policy, and humanity.
Leave a Reply